Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LU… Read more
Market Cap & Net Worth: Rosetta Genomics Ltd (ROSGQ)
Rosetta Genomics Ltd (PINK:ROSGQ) has a market capitalization of $592.99 ($592.99) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #49633 globally and #15177 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rosetta Genomics Ltd's stock price $0.00 by its total outstanding shares 5929860 (5.93 Million).
Rosetta Genomics Ltd Market Cap History: 2015 to 2025
Rosetta Genomics Ltd's market capitalization history from 2015 to 2025. Data shows change from $87.52 Million to $592.99 (-73.40% CAGR).
Rosetta Genomics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rosetta Genomics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.24x
Rosetta Genomics Ltd's market cap is 3.24 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $87.52 Million | $8.27 Million | -$17.34 Million | 10.59x | N/A |
| 2016 | $29.89 Million | $9.23 Million | -$16.23 Million | 3.24x | N/A |
Competitor Companies of ROSGQ by Market Capitalization
Companies near Rosetta Genomics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Rosetta Genomics Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Rosetta Genomics Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Rosetta Genomics Ltd's market cap moved from $87.52 Million to $ 592.99, with a yearly change of -73.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $592.99 | 0.00% |
| 2024 | $592.99 | 0.00% |
| 2023 | $592.99 | 0.00% |
| 2022 | $592.99 | 0.00% |
| 2021 | $592.99 | -99.50% |
| 2020 | $118.60K | +566.67% |
| 2019 | $17.79K | +130.77% |
| 2018 | $7.71K | -99.77% |
| 2017 | $3.29 Million | -88.99% |
| 2016 | $29.89 Million | -65.85% |
| 2015 | $87.52 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Rosetta Genomics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $592.99 USD |
| MoneyControl | $592.99 USD |
| MarketWatch | $592.99 USD |
| marketcap.company | $592.99 USD |
| Reuters | $592.99 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.